Skip to main content

Table 5 US FDA-approved human mAbs

From: Development of therapeutic antibodies for the treatment of diseases

No.

Antibody

Brandname

Company

Approval#

Target

References

Technology

1

Adalimumab

Humira

Abbott_Laboratories

2002

TNFα

den Broeder et al. [178]

Phage display

2

Panitumumab

Vectibix

Amgen

2006

EGFR

Tyagi et al. [179]

XenoMouse

3

Ustekinumab

Stelara

Johnson & Johnson

2009

IL-12

Bartlett et al. [17]

HuMabMouse

4

Canakinumab

Ilaris

Novartis

2009

IL-1β

Church et al. [18]

HuMabMouse

5

Golimumab

Simponi

Johnson & Johnson/Merck

2009

TNFα

Zhou et al. [19]

HuMabMouse

6

Ofatumumab

Arzerra

GlaxoSmithKline (Genmab)

2009

CD20

Coiffier et al. [20]

HuMabMouse

7

Denosumab

Prolia, Xgeva

Amgen

2010

RANKL

Reddy et al. [21]

XenoMouse

8

Belimumab

Benlysta

GlaxoSmithKline

2011

BCAF

Ding et al. [180]

Phage display

9

Ipilimumab

Yervoy

Bristol-Myers Squibb

2011

CTLA-4

Morse et al. [22]

HuMabMouse

10

Ramucirumab

Cyramza

Eli Lilly (ImClone)

2014

VEGFR2

Krupitskaya et al. [181]

Phage display

11

Nivolumab

Opdivo

Bristol-Myers Squibb

2014

PD-1

Wolchok et al. [23]

HuMabMouse

12

Alirocumab

Praluent

Sanofi and Regeneron

2015

PCSK9

Roth et al. [24]

Veloclmmune Mouse

13

Daratumumab

Darzalex

Johnson & Johnson (Genmab)

2015

CD38

de Weers et al. [25]

HuMabMouse

14

Necitumumab

Portrazza

Eli Lilly (ImClone)

2015

EGFR

Kuenen et al. [182]

Phage display

15

Evolocumab

Repatha

Amgen

2015

PCSK9

Hirayama et al. [26]

XenoMouse

16

Secukinumab

Cosentyx

Novartis

2015

IL-17α

Chioato et al. [27]

XenoMouse

17

Olaratumab

Lartruvo

Eli Lilly

2016

PDGFRα

Chiorean et al. [28]

HuMabMouse

18

Atezolizumab

Tecentriq

Roche

2016

PD-L1

McDermott et al. [183]

Phage display

19

Avelumab

Bavencio

Pfizer

2017

PD-L1

Boyerinas et al. [184]

Phage display

20

Brodalumab

Siliq

Valeant Pharmaceuticals

2017

IL-17R

Papp et al. [29]

XenoMouse

21

Dupilumab

Dupixent

Sanofi and Regeneron

2017

IL-4R

Wenzel et al. [30]

Veloclmmune Mouse

22

Durvalumab

Imfinzi

Medimmune/AstraZeneca

2017

PD-L1

Antonia et al. [31]

XenoMouse

23

Guselkumab

Tremfya

Jassen Biotech

2017

IL-23

Sofen et al. [185]

Phage display

24

Sarilumab

Kevzara

Sanofi and Regeneron

2017

IL-6R

Huizinga et al. [32]

Veloclmmune Mouse

25

Erenumab

Aimovig

Novartis and Amgen

2018

CGRPR

Tepper et al. [33]

XenoMouse

26

Cemiplimab

Libtayo

Regeneron

2018

PD-1

Migden et al. [34]

Veloclmmune Mouse

27

Emapalumab

Gamifant

NovImmmune

2018

IFNγ

Al-Salama ZT [186]

Phage display

28

Moxetumomab pasudodox

Lumoxiti

MedImmune/AstraZeneca

2018

CD22

Kreitman et al. [187]

Phage display

  1. #Year of the first US FDA approval